Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC280 + Cetuximab in c-MET positive mCRC and HNSCC
NCT02205398Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jul 2014
- Primary completion
- Jan 2017
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of capmatinib in colorectal cancer (CRC) and head and neck squamous cell carcinoma (HNSCC), sponsored by Novartis. Primary endpoint: Incidence of Dose Limiting Toxicities up to 4 weeks. Started Jul 2014; status: terminated.
02
Drugs
capmatinib
03
Conditions
colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02205398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205398.